A Novel Approach to Platinum-Resistant Ovarian Cancer: Results from the Elenagen Phase II Study (ESGO 2026)

Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC). The oral presentation, titled Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer (Abstract 274), detailed results from a randomized Phase II clinical trial evaluating the DNA-based therapy Elenagen (p62/SQSTM1-encoding plasmid) in combination with gemcitabine. Dr. Levin’s presentation took place on Feb 27, 2026.